Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1545
  • Dowloads 145

Case Reports

Open Access

Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report

  • P. Azevedo1
  • C. F. Verschraegen1,*,
  • J. J. Kavanagh1
  • A. P. Kudelka1
  • R. S. Freedman1
  • K. Lu1
  • M. T. Deavers1

1Multidisciplinary Gynecologic Cancer Center, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA

DOI: 10.12892/ejgo200105319 Vol.22,Issue 5,September 2001 pp.319-321

Published: 10 September 2001

*Corresponding Author(s): C. F. Verschraegen E-mail:

PDF (385.66 kB) View Full-text

Keywords

Mixed Mullerian Tumor; Irinotecan

Cite and Share

P. Azevedo, C. F. Verschraegen, J. J. Kavanagh, A. P. Kudelka, R. S. Freedman, K. Lu, M. T. Deavers. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. European Journal of Gynaecological Oncology. 2001; 22(5): 319-321. doi: 10.12892/ejgo200105319

URL:

https://www.ejgo.net/articles/10.12892/ejgo200105319

References

[1] Krishnan E., Coleman R. E.: "Malignant mixed mullerian tumours of gynaecological origin: chemosensitive but aggressive tumours". Clinical Oncology (Royal College of Radiologists), 1998, 10(4), 246.

[2] Pfeiffer P. et al.: "Malignant mixed mullerian tumors of the ovary. Report of 13 cases". Acta Obstetricia et Gynecologica Scandinavica, 1991, 70(1), 79.

[3] Verschraegen C.F., Edwards C. L., Fox H.: "Present knowledge of gynecologic sarcoma management". Hematology Oncology Clinics of North America, I 999, 13(1), 211.

[4] Silverberg S. G. et al.: "Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases". International Journal of Gynecological Pathology, 1990, 9(1), 1.

[5] Rose P. G., Rodriguez M., Abdul-Karim F. W.: "Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases". Gynecologic Oncology, 1997, 65(3), 523.

[6] Olah K.S., Dunn J. A., Gee H.: "Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma". British Journal of Obstetrics & Gynaecology, 1992, 99(7), 590.

[7] Resnik E. et al.: "A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus". Gynecologic Oncology, 1995, 56(3), 370.

[8] Kohorn E. I. et al.: "Adjuvant therapy in mixed mullerian tumors of the uterus". Gynecologic Oncology, 1986, 23(2), 212.

[9] Knocke T. H. et al.: "Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri" Gynecologic Oncology, 1999, 73(3), 389.

[10] Gonzalez-Bosquet E. et al.: "Uterine sarcoma: a clinicopathological study of 93 cases". European Journal of Gynaecological Oncology, 1997, 18(3), 192.

[11] Major F. J. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71 (4 Suppl), 1702.

[12] Sutton G. P. et al.: "A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study". Gynecologic Oncology, 1994, 53(1), 24.

[13] Thigpen J. T. et al.: "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study". Cancer Treatment Reports, I 986, 70(2), 271.

[14] Thigpen J. T. et al.: "Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study [see comments]'' Journal of Clinical Oncology, 1991, 9(11), 1962.

[15] Grosh W. W. et al.: "Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy". Gynecologic Oncology, 1986, 25(3), 334.

[16] Baker T. R. et al.: "Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary [published erratum appears in Am. J. Clin. Oncol., 1991 Oct., 14(5), 455]. American Journal of Clinical Oncology, 1991, 14(3), 246.

[17] Andersen W. A. et al.: "Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary". Gynecologic Oncology, 1989, 32(3), 319.

[18] Eltabbakh G. H., Yadav R.: "Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy". European Journal of Gynaecological Oncology, 1999, 20(5-6), 355.

[19] Slayton R. E. et al.: "Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study". Cancer Treat Rep., 1987, 71(6), 661.

[20] Clement P. B., Oliva E., Young R. H.: "Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions". International Journal,)fGynecological Pathology, 1996, 15(3), 222.

[21] Olah K. S.: "Ut erine carcinosarcoma in association with tamoxifen therapy [letter; comment]". British Journal of Obstetrics &Gynaecology, 1997, 104(12), 1420.

[22] Muthuphei M. N., Maluleke H. J.: "Malignant mixed mullerian tumours of the body of the uterus: a clinicopathological study of 20 cases". Central African Journal of Medicine, 1998, 44(2), 45.

[23] Thigpen J. T. et al.: "Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study". American Journal of Clinical Oncology, 1985, 8(5), 350.

[24] Muss H. B. et al.: "Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group". American Journal of Clinical Oncology, 1990, 13(1), 32.

[25] Muss H. B. et al.:'Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)". Cancer, 1985, 55(8), 1648.

[26] Resnik E. et al.: "Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy". Journal of Surgical Oncology, 1996, 63(3), 145.

[27] Kavanagh J. J., Verschraegen C. F., Kudelka A. P.: "lrinotecan in cervical cancer. [Review]". Oncology, I 998, 12(8 Suppl 6), 94.

[28] Haluska P.. Rubin E., Verschraegen C.: "Topoisomerase-I inhibi－tors in gynecologic tumors". Hematology/Oncology C linics of North America, 1999, 13(1).

[29] Sugiyama T. et al.: "Irinotecan (CPT-11) combined with cisplatm in patients with refractory or recurrent ovarian cancer". Cancer Letters, 1998, 128(2), 211.

[30] Sugiyama T. et al.: "Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer". British Journal of Cancer, 1999, 81(1), 95.

[31] Gerrits C .J. et al.: "Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development". Br. J Cancer, 1997, 76(7), 952.

Submission Turnaround Time

Top